Prot #MCLA-128-CL02: Phase 2 Study of MCLA-128-based Combinations in Metastatic Breast Cancer (MBC): MCLA-128/Trastuzumab/Chemotherapy in HER2-Positive MBC and MCLA-128/Endocrine Therapy in Estrogen Receptor Positive and Low HER2 Expression MBC

Project: Research project

Project Details

StatusFinished
Effective start/end date8/7/18 → 8/7/21

Funding

  • SCRI Development Innovations, LLC (Prot #MCLA-128-CL02)
  • Merus N.V. (Prot #MCLA-128-CL02)